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Purpose. We report a series of 58 patients with metastatic bone disease treated with resection and endoprosthetic reconstruc-
tion over a ﬁve-year period at our institution. Introduction. The recent advances in adjuvant and neoadjuvant therapy in cancer
treatment have resulted in improved prognosis of patients with bone metastases. Most patients who have either an actual or im-
pending pathological fracture should have operative stabilisation or reconstruction. Endoprosthetic reconstructions are indicated
in patients with extensive bone loss, failed conventional reconstructions, and selected isolated metastases. Methods and Results.
We identiﬁed all patients who were diagnosed with metastatic disease to bone between 1999 and 2003. One hundred and seventy-
one patients were diagnosed with bone metastases. Metastatic breast and renal cancer accounted for 84 lesions (49%). Fifty-eight
patients with isolated bone metastasis to the appendicular skeleton had an endoprosthetic reconstruction. There were 28 males
and 30 females. Twelve patients had an endoprosthesis in the upper extremity and 46 patients had an endoprosthesis in the lower
extremity. The mean age at presentation was 62 years (24 to 88). At the time of writing, 19 patients are still alive, 34 patients have
died, and 5 have been lost to follow up. Patients were followed up and evaluated using the musculoskeletal society tumour score
(MSTS) and the Toronto extremity salvage score (TESS). The mean MSTS was 73% (57% to 90%) and TESS was 71% (46% to
95%). Mean follow-up was 48.2 months (range 27 to 82 months) and patients died of disease at a mean of 22 months (2 to 51
months) from surgery. Complications included 5 superﬁcial wound infections, 1 aseptic loosening, 4 dislocations, 1 subluxation,
and 1 case, where the tibial component of a prosthesis rotated requiring open repositioning. Conclusions. We conclude that endo-
prosthetic replacement for the treatment of isolated bone metastases is a reliable method of limb reconstruction in selected cases.
It is associated with low complication and failure rates in our series, and achieves the aims of restoring function, allowing early
weight bearing and alleviating pain.
Copyright © 2007 D. H. Park et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Bony metastases are the most common neoplasms of bone
andtheskeletonisthethirdmostcommonsiteformetastatic
diseases, after the lung and liver [1]. Advances in adjuvant
and neoadjuvant therapies, especially in the ﬁelds of hor-
monal therapy and chemotherapy, have improved the prog-
nosis of patients with cancer. This has subsequently led to
an increase in the incidence of bony metastases and resultant
pathological fractures of the long bones. The management
of the patient with a pathological fracture presents a chal-
lenge to the orthopaedic surgeon and necessitates a multidis-
ciplinary approach. A consensus statement by the British Or-
thopaedic Association and the British Orthopaedic Oncol-
ogy Society has highlighted the fact that there remains a low
levelofawarenessinthehospitalandprimary-caresettingsof
what can be achieved in the management of metastatic bone
diseases [2, 3]. Skeletal complications can have a marked ef-
fect on the patient’s quality of life, with bone pain being
the most frequent clinical symptom. An actual or impending
pathological fracture impacts on the patient’s function and
mobility. In principle, the aims of treatment should be to
relieve pain and restore function by stabilising pathological
fractures [2, 4–6]. Stabilising impending of actual patholog-
ical fractures allows early resumption of ambulation, which
signiﬁcantly improves patients’ quality of life [7]. In addi-
tiontostabilisation,orthopaedicconstructsshouldallowim-
mediate weight bearing and be designed to last the expected
lifetime of the patient [2, 8]. Fracture healing is often poor
in diseased or irradiated bone and the surgeon must take
into account the fact that these fractures may not unite [9].
Metastatic lesions with extensive bone loss or pathological2 Sarcoma
fractures aﬀecting adjacent joints may be treated with resec-
tionandanendoprostheticreconstruction.Theload-bearing
characteristics of endoprosthesis oﬀer immediate postopera-
tive stability, and facilitate rapid rehabilitation [10, 11]. Over
the last 20 years, the availability and improvement of modu-
larendoprosthesishaveimprovedthetreatmentofmetastatic
bone disease, particularly in the treatment of isolated bone
metastasis, failed conventional reconstructions and lesions
with extensive bone loss [12]. In selected cases, isolated le-
sions such as a metastasis from renal cell cancer are treated
with complete excision and endoprosthetic reconstruction
with the intent to cure [4, 13].
The purpose of this paper is to review our experience of
patients with metastatic bone disease from carcinoma that
had resection and an endoprosthetic reconstruction at our
hospital over a ﬁve-year period.
2. METHODS
Weperformedaretrospectivereviewofallpatientswithbone
metastases referred to our regional musculoskeletal tumour
centre from January 1999 to December 2003. Patients were
identiﬁed from the tumour database. We determined the pa-
tient demographics, indications for treatment and the com-
plications in patients who had resection of metastatic bone
lesions and endoprosthetic reconstruction. The following in-
clusion criteria are applied for the sample collection: (1) a
known metastatic lesion in the appendicular skeleton on the
basis of histological diagnosis; and (2) no previous resec-
tion and endoprosthetic reconstruction. Other information,
namely, age, gender, primary lesion if known, site of lesion,
and duration of follow-up period, were also noted. All pa-
tients referred to our institution are discussed in a multidis-
ciplinary team setting, attended by oncologists, radiologists,
orthopaedic surgeons, and other allied health professionals.
Decisions regarding prophylactic surgery for patients with
impending pathological fractures are made based on Mirels
[14]scoringsystem(Table 1),withascoreof>8necessitating
operative stabilisation.
The indications for endoprosthetic reconstruction were
isolated single metastases in the long bones, lesions involv-
ingadjacentjoints,andlargelesionswithextensiveboneloss.
In principle, these metastatic lesions were excised in a simi-
lar manner to primary bone tumours. Where possible, wide
soft tissue margins were obtained and the shaft of the long
bone was transected at least 2cm away from the extent of the
disease. In view of the fact that this is palliative surgery, im-
portant neurovascular structures were usually preserved at
the expense of wide margins in order to maximise functional
outcome. In patients with intraarticular spread of tumour,
we performed conventional joint replacement surgery and
did not attempt extraarticular resections. In the case of prox-
imal femoral, distal femoral and proximal tibial reconstruc-
tion modular endoprosthetic tumour system (METS, Stan-
more Implants Worldwide Ltd, Stanmore, Middlesex, UK)
were used as it became available. For the proximal femoral
replacements, this was in 2001 and for the distal femoral
and proximal tibial replacements, this was in 2003. These
Table 1: Mirels’ Scoring System.
Variable Score
12 3
Site Upper limb Lower limb Peritrochanter
Pain Mild Moderate Functional
Lesion Blastic Mixed Lytic
Size∗ <1/3 1/3-2/3 >2/3
∗As seen on plain X-ray, minimum destruction of cortex in any view.
Maximum possible score is 12. If lesion scores 8 or above, then
prophylactic ﬁxation is recommended prior to surgery.
above-mentioned prostheses are modular, oﬀ-the-shelf en-
doprosthetic reconstruction systems. For other tumour loca-
tions and before these dates, surgery required the manufac-
ture of custom-made implants (Stanmore Implants World-
wide Ltd).
In patients requiring proximal femoral replacement and
whose disease spared the greater trochanter, this structure
was osteotomised and reattached to the endoprostheses us-
ing a trochanteric reattachment plate and screws. The prox-
imal femoral endoprostheses contain a spiked, hydroxyap-
atite coated shoulder with two screw holes for this speciﬁc
purpose. This enables gluteus medius and minimus to be
reattached thereby preserving abductor function. Postopera-
tiveradiotherapywasoﬀeredtoallpatientswithpathological
fractures and those whose resection margins were positive.
We did not routinely oﬀer radiotherapy to patients who had
a successful wide excision.
Functional outcome was assessed using the system
adopted by the musculoskeletal tumour Society (MSTS) for
the functional evaluation of reconstructive procedures after
skeletal resection [15], and a patient-reported measure of
disability, the Toronto extremity salvage score (TESS) [16].
The MSTS score is a clinician scored system assessing pain,
function,andemotionalacceptanceinpatientsforupperand
lower extremities. Patients with lower extremity reconstruc-
tions were also evaluated with regard to walking ability, gait,
and the use of walking aids. Patients with upper extremity
reconstructions were evaluated for manual dexterity, hand
positioning, and lifting ability. The TESS was developed as
a disease-speciﬁc measure for patients undergoing limb sal-
vage surgery for tumours of the extremity. It evaluates phys-
ical disability based on the patients’ report of their function
using a self-administered questionnaire, which rates the dif-
ﬁculty experienced in performing certain activities. Both the
MSTS and TESS scores are represented as a percentage, with
a higher percentage indicating better functional outcome.
3. RESULTS
Between January 1999 and December 2003, 171 patients
were diagnosed with metastatic bone tumours from carci-
noma. Fifty-eight of which underwent an endoprosthetic re-
construction. There were 28 males and 30 females with a
mean age at diagnosis of 62 years (range 24 to 88). The most
common underlying diagnosis was renal cell carcinoma inD. H. Park et al. 3
Table 2: Primary diagnosis of patients undergoing endoprosthetic
reconstruction.
Primary diagnosis Number (%)
Renal carcinoma 27 (46.6)
Breast carcinoma 10 (17.2)
Unknown primary 8 (13.8)
Lung carcinoma 4 (6.9)
Squamous cell carcinoma 2 (3.4)
Prostate carcinoma 2 (3.4)
Thyroid carcinoma 1 (1.7)
Oesophageal carcinoma 1 (1.7)
Phaeochromocytoma 1 (1.7)
Ovarian carcinoma 1 (1.7)
Bladder carcinoma 1 (1.7)
27 (46.6%) of patients, followed by breast carcinoma in 10
(17.2%), unknown primary carcinoma in 8 (13.7%), lung
carcinomain4,squamouscellcarcinomain2,prostatecarci-
noma in 2, thyroid, oesophageal, ovarian, and bladder carci-
nomain1patienteachandaphaeochromocytoma(Table 2).
Forty-six patients had lower extremity lesions, which were
treated with 31 proximal femoral replacements, 11 distal
femoral replacements, and 4 proximal tibial replacements.
Twelve had upper extremity lesions, treated with 7 proximal
humeral replacements, 4 distal humeral replacements, and 1
humeral diaphyseal replacement.
T h e r ew e r e5s u p e r ﬁ c i a lw o u n di n f e c t i o n s( 8 . 6 % ) ,a l lo f
which resolved with oral antibiotics. Four dislocations oc-
curred in the proximal femoral replacements group (12.9%).
Three were reduced closed and one required an open re-
ductionwithoutrequiringcomponentrepositioningandthis
patient was subsequently managed in an abduction brace
for 8 weeks. There was one case of aseptic loosening in the
humeral diaphyseal replacement, which required revision,
onesubluxationinaproximalhumeralreplacement,andone
case of component malposition. The tibial component of a
distal femoral replacement was found to be rotated 180 de-
grees requiring open exploration and repositioning.
Thirty-four patients had died at a mean of 22 months
(range2to51months)fromsurgeryand5werelosttofollow
up. The remaining 19 had a mean follow-up of 48.2 months
(range 27 to 82 months). They were functionally evaluated
with the MSTS and the TESS scores (Table 3). For the group
as a whole, the mean MSTS score was 73% (range from 57 to
90%) and TESS was 71% (range 46 to 95%). Looking speciﬁ-
cally at lower limb reconstruction, the mean MSTS score was
77.9% (range 57 to 90%) and the mean TESS was 75.6%
(range 46 to 95%). The group with proximal femoral re-
placements (11 patients) had a mean MSTS score of 72.4%
(range 57 to 83) and a mean TESS of 68.4% (range 46 to
84). The group with distal femoral replacements (4 patients)
had a mean MSTS score of 75% (range 60 to 90) and a mean
TESS of 77.5% (range 63 to 95). One patient with a proximal
tibial replacement had an MSTS score of 73% and a TESS
score of 72%. In the upper limb, two patients with proximal
humeral replacements had MSTS scores and TESS of 72%
and 70%, and 73% and 71%, respectively. One patient with a
distal humeral replacement had an MSTS score of 76% and a
TESS of 77%.
No patients had local recurrence or required subsequent
amputation and there was one revision of the humeral dia-
physeal replacement as described above.
4. DISCUSSION
Endoprosthetic reconstruction has a role in the management
of metastatic lesions with extensive bone loss, failure of con-
ventional reconstruction, and large isolated lesions with the
aim being curative. Although the conventional treatment of
metastatic bone lesions with plates and intramedullary de-
vices supplemented with methylmethacrylate is well estab-
lished [7], lesions that involve adjacent joints often require
resection and reconstruction to allow early and full weight
bearing. The purpose of this study was to review our expe-
rience with endoprosthetic replacements and to objectively
assess patient outcome using both a clinician-reported and
a patient-reported score. The majority of the endoprosthetic
reconstructions in our series were proximal femoral replace-
ments, a ﬁnding reﬂected in other series of endoprosthetic
replacements for bone metastases [5, 12], with the proxi-
mal femur being the most common site of long-bone in-
volvement by metastatic disease [8, 17, 18]. The hip joint
must bear as much as six times body weight and this ne-
cessitates that reconstruction must provide immediate sta-
bility and prolonged durability. This strongly favours the use
of an endoprosthetic replacement rather than internal ﬁxa-
tion [8]. Conventional ﬁxation of pathological fractures or
large lytic lesions especially around the hip or proximal fe-
mur has a high failure rate when compared to a standard or
tumour prosthetic replacement [5, 19, 20]. It is therefore our
preferred method of treatment to carry out a resection and
endoprosthetic replacement for large lesions of the proximal
femur. The extent of tumour in the proximal femur dictated
the method of abductor repair and if the trochanter could be
sparedwithanadequatemarginofbonebetweenthetumour
and a trochanteric osteotomy, then the trochanter was reat-
tached in the manner described previously. Tumour involv-
ingthetrochanterresultedinresectionoftheproximalfemur
includingthetrochanterandasofttissueabductorrepairwas
done. In our series of 11 patients, only one patient was suit-
able for a trochanteric osteotomy and reattachment to the
prosthesis. This patient subsequently had a dislocation on
herﬁrstpostoperativedayandunderwentaclosedreduction.
At 31 months follow-up, her MSTS score was 57% and her
TESS was 46%. Due to the small numbers we are unable to
commentonwhethertrochantericreattachmentsigniﬁcantly
aﬀects functional outcome or hip abductor function. Of the
11 patients with proximal femoral lesions, seven presented
with a pathological fracture. Patients who had a pathological
fracture on presentation had a mean MSTS score of 69.1%
(range 57 to 80%) and a mean TESS of 65.9% (46 to 82%).
Patients who presented without a pathological fracture had
a mean MSTS score of 78% (range 70 to 83%) and a mean4 Sarcoma
Table 3: Functional outcomes of the 19 patients (out of 58) surviving 2 years or more.
Patient Primary Age Operation∗ TESS MSTS Follow-up (months)
1 Phaeochromocytoma 24 PFR 82 80 39
2 Thyroid carcinoma 42 PFR 72 74 41
3 Oesophageal carcinoma 42 PFR 69 63 35
4 Ovarian carcinoma 45 PFR 65 77 33
5 Breast carcinoma 49 PFR 46 57 31
6 Renal carcinoma 67 PFR 56 63 31
7 Unknown primary 77 PFR 71 70 44
8 Unknown primary 58 PFR 74 78 44
9 Breast carcinoma 68 PFR 53 70 27
10 Breast carcinoma 42 PFR 84 83 58
11 Renal carcinoma 36 PFR 80 81 46
12 Squamous cell carcinoma 49 PTR 72 73 28
13 Renal carcinoma 46 DFR 72 71 82
14 Breast carcinoma 50 DFR 95 90 35
15 Renal carcinoma 56 DFR 80 79 66
16 Renal carcinoma 61 DFR 63 60 73
17 Renal carcinoma 52 PHR 71 73 73
18 Renal carcinoma 54 PHR 70 72 60
19 Unknown primary 59 DHR 77 76 60
∗PFR = proximal femoral replacement, PHR = proximal humeral replacement, PTR = proximal tibial replacement, DFR = distal femoral replacement,
DHR = distal humeral replacement.
TESSof72.8%(range53to84%).Thediﬀerenceinscoresare
not statistically signiﬁcant and larger studies will be required
to determine if patients who present with pathological frac-
tures have poorer functional outcome scores compared to
patients who do not. With regard to overall functional out-
come, patients with proximal femoral replacements had a
mean MSTS score of 72.3% (range 57 to 83%) and a mean
TESS score of 68.4% (range 46 to 84%). These scores com-
pare to those reported in other series of proximal femoral
endoprosthetic replacements using modular endoprostheses
[21, 22].
Table 3 shows the functional outcomes of all the patients
who survived 2 years or more who were treated with an en-
doprosthetic replacement. The functional outcomes for pa-
tients with upper and lower limb reconstructions are com-
parable; however, the number of patients followed up with
upper limb reconstructions (three) is too small for any fur-
ther signiﬁcant conclusions.
There were ﬁve cases of superﬁcial infection which re-
solved with oral antibiotics alone, but no cases of deep in-
fection. In 58 endoprosthetic replacements, only one patient
requiredarevisionforasepticlooseningofahumeraldiaphy-
seal replacement. There were four dislocations in the group
of patients who had proximal femoral replacements (31 pa-
tients). All dislocations occurred within the ﬁrst 3 weeks of
surgery.Threewerereducedclosedandonerequiredanopen
reduction without the need for component repositioning.
They were all rehabilitated postreduction in an abduction
brace for 8 to 10 weeks. None of these patients experienced
any further dislocations. Two of these patients survived more
than 2 years and in the latest follow-up, they were mobilising
with one walking stick. Functionally their MSTS scores and
TESS were 57% and 46%, and 70% and 53%, respectively.
The mean time to death of the 58 patients was 22 months
(range 2 to 51 months). This wide range highlights the need
for a stable reconstruction that allows early weight bearing,
has a low incidence of failure, and outlasts the expected life-
time of the patient.
Our series was associated with relatively few, easily man-
ageable complications and there were no implant failures.
Massive endoprostheses were originally developed for
the treatment of primary malignant bone tumours. They
have traditionally been custom-designed and hence there
was a time delay to manufacture the implant. The grad-
ual introduction of modular endoprostheses has provided
greater ﬂexibility making these reconstructions possible, and
in shorter time frames, therefore aiding the overall manage-
ment of metastatic bone disease. According to British Or-
thopaedic Association guidelines [2], patients should un-
dergo a single procedure that allows early full weight bearing
and lasts the expected lifespan of the patient. In our experi-
ence the use of an endoprostheses allows these criteria to be
met.
Appropriate and prompt surgical management of
metastatic bone lesions may be more cost-eﬀective in terms
of the overall management of cancer patients. This is re-
ﬂected in earlier mobilisation and therefore potentially less
time spent in hospital. Other studies are needed to assess the
impact of these cost savings on hospital, nursing, and com-
munity cancer services. Patients who had an endoprostheticD. H. Park et al. 5
reconstruction in our series were able to return to a good
level of function.Careful patient selection is crucial and the
surgeon must take into consideration the patient’s progno-
sis, comorbidities, and their ability to participate in postop-
erative rehabilitation.
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